1) receptor domain
受体死亡域
2) death receptor
死亡受体
1.
Expression of death receptor 5 (DR5) in the cells of acute non-lymphocyte leukemia (ANLL) and its clinical significance;
死亡受体DR5在急性非淋巴细胞白血病细胞中的表达及其临床意义
2.
Methods TRAIL death receptor DR4,DR5,FADD were detected by Western-blot analysis.
方法用Western-blot法检测胆囊癌细胞株中TRAIL死亡受体DR4、DR5和Fas相关死亡结构域(fas-associated death domain,FADD)的表达状况,生长曲线、相差显微镜和流式细胞仪观测rhTRAIL作用于胆囊癌细胞株后的细胞生长状况。
3.
Expression of death receptor DR4 and DR5 were measured by immunofluorescence microscopy and flow cytometry.
应用流式细胞仪检测细胞周期、凋亡峰、死亡受体DR4和DR5分子及黏附分子VLA4(CD49d)的表达;用聚合酶链反应测定靶细胞CXCR4基因表达;免疫组化染色和荧光显微镜检测DR4和DR5分子的表达情况。
5) Death receptor 5
死亡受体5
1.
Construction and expression of extracellular domain of human death receptor 5 and detection of its biological activity;
死亡受体5胞外区域的重组、表达及活性鉴定
2.
We have previously prepared a novel monoclonal agonistic antibody against human death receptor 5 (DR5) and designated it as mDRA-6.
我们研制了抗人死亡受体5(death receptor,DR5)功能性单克隆抗体(mDRA-6),本研究对其诱导Jurkat细胞凋亡的Caspase分子机制进行初步探讨。
6) DR5
死亡受体5
1.
This study aim to investigate the effect of H/R on the expression of death receptor 5(DR5)and TRAIL cytotoxicity,hope to find the causes of hepatic is.
目的:研究肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)/死亡受体5(Death receptor 5,DR5)途径在人肝细胞缺氧/再给氧(Hypoxia/reoxygenation,H/R)损伤中的作用,并探讨其作用机制。
2.
Objective: To construct eukaryotic expression vector of human death receptor(DR5) and transfect NS-1 cells to establish stable NS-1 cell line.
目的:构建人死亡受体5(DR5)真核表达载体,转染NS-1细胞,建立稳定转染的NS-1细胞系。
补充资料:超导电性的局域和非局域理论(localizedandnon-localizedtheoriesofsuperconductivity)
超导电性的局域和非局域理论(localizedandnon-localizedtheoriesofsuperconductivity)
伦敦第二个方程(见“伦敦规范”)表明,在伦敦理论中实际上假定了js(r)是正比于同一位置r的矢势A(r),而与其他位置的A无牵连;换言之,局域的A(r)可确定该局域的js(r),反之亦然,即理论具有局域性,所以伦敦理论是一种超导电性的局域理论。若r周围r'位置的A(r')与j(r)有牵连而影响j(r)的改变,则A(r)就为非局域性质的。由于`\nabla\timesbb{A}=\mu_0bb{H}`,所以也可以说磁场强度H是非局域性的。为此,超导电性需由非局域性理论来描绘,称超导电性的非局域理论。皮帕德非局域理论就是典型的超导电性非局域唯象理论。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条